June 28, 2017 11:42 PM ET

Pharmaceuticals

Company Overview of Janssen Pharmaceutical K.K.

Company Overview

Janssen Pharmaceutical K.K. develops, manufactures, and markets prescribed pharmaceutical products. It manufactures medicines for oncology, immunology, CNS disorders, pain management, and infectious diseases. Janssen Pharmaceutical K.K. was formerly known as Janssen-Kyowa Co., Ltd. Janssen Pharmaceutical K.K. was formerly known as Janssen-Kyowa Co., Ltd. and changed its name to Janssen Pharmaceutical K.K. in March 2002. The company was founded in 1978 and is based in Shizuoka, Japan. Janssen Pharmaceutical K.K. operates as a subsidiary of Johnson & Johnson.

600-8, Minami-isshiki

Nagaizumicho

Sunto-gun

Shizuoka,  411-0932

Japan

Founded in 1978

Phone:

81 3 3445 2211

Fax:

81 3 3445 2366

Key Executives for Janssen Pharmaceutical K.K.

President
Compensation as of Fiscal Year 2016.

Janssen Pharmaceutical K.K. Key Developments

Mitsubishi Tanabe Pharma Corporation Signs Co-Promotion Agreement with Janssen Pharmaceutical K.K

Mitsubishi Tanabe Pharma Corporation signed a co-promotion agreement with Janssen Pharmaceutical K.K. for STELARA (ustekinumab) for an indication of Crohn's disease. Janssen has filed an application in Japan for this indication for STELARA, a monoclonal antibody that binds to the p40 subunit of human anti-interleukin (IL)-12 and IL-23. Under the terms of this agreement, after Janssen obtains approval for this indication, Janssen will conduct to distribution while the two companies will jointly promote STELARA.

Janssen Pharmaceutical K.K. Submits a New Drug Application to the Ministry of Health, Labor and Welfare

Janssen Pharmaceutical K.K. has submitted a New Drug Application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for the use of daratumumab (DARZALEX®) for the treatment of adults with relapsed or refractory multiple myeloma. The submission of the application triggers milestone payments totaling USD 10 million to Genmab from Janssen. Genmab is updating its financial guidance for 2016 to include the milestones. In August 2012, Genmab granted Janssen Biotech Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

Janssen Pharmaceutical K.K. Announces Submission of New Drug Application for Daratumumab

Genmab A/S has announced that Janssen Pharmaceutical K.K. has submitted a New Drug Application to the Ministry of Health, Labor and Welfare, or MHLW, in Japan for the use of daratumumab (DARZALEX) for the treatment of adults with relapsed or refractory multiple myeloma. The submission of the application triggers milestone payments totaling USD 10 million to Genmab from Janssen. Genmab is updating its financial guidance for 2016 to include the milestones. In August 2012, Genmab granted Janssen Biotech Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

Similar Private Companies By Industry

Company Name Region
ABsize Inc. Asia
AccuRna, Inc. Asia
ACE Japan, L.L.C. Asia
AETAS Pharma Co.,Ltd. Asia
AIP Corporation Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Janssen Pharmaceutical K.K., please visit www.janssen.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.